Eli Lilly and Company PE Ratio: 10.08
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LLY PE Ratio Rankings
| Overall | 82nd percentile | 575 of 3211 |
| Sector | 83rd percentile | 42 of 259 in Healthcare |
| Industry | 75th percentile | 4 of 16 in Drug Manufacturers - Major |
LLY PE Ratio Range, Past 5 Years
| Minimum | 11.18 | Sep 1993 |
| Maximum | 48.87 | Jun 2005 |
| Average |
About Price to Earnings Ratio
The price to earnings ratio (PE Ratio) is the measure of the share price relative to the annual net income earned by the firm per share. PE ratio shows current investor demand for a company share. A high PE ratio generally indicates increased demand because investors anticipate earnings growth in the future. The PE ratio has units of years, which can be interpreted as the number of years of earnings to pay back purchase price.
PE ratio is often referred to as the "multiple" because it demonstrates how much an investor is willing to pay for one dollar of earnings. PE Ratios are sometimes calculated using estimations of next year's earnings per share in the denominator. When this happens, it is usually noted.
Learn More
You may also be interested in these LLY related companies
LLY News
Diabetes Self-Management Magazine|FDA Approves Combo Type 2 Medicine http://stks.co/2MCG $LLY
about a day ago by abubnic
about a day ago by abubnic
FDA approves $LLY Jentadueto™tablets for the treatment of adult patients with type 2 diabetes. http://stks.co/2MCA
about a day ago by abubnic
about a day ago by abubnic
Notable Stocks Trading Ex-Dividend Monday 02/13: (STX) (LLY) (IP) (EXC) (DD)
Feb 10, 10:57AM Street Insider
Feb 10, 10:57AM Street Insider
Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co.
Feb 09, 9:00AM Marketwire
Feb 09, 9:00AM Marketwire
Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
Feb 09, 8:00AM PR Newswire
Feb 09, 8:00AM PR Newswire
AMAG Pharmaceuticals (AMAG) Adds Rajiv De Silva and Gino Santini to Board
Feb 07, 4:31PM Street Insider
Feb 07, 4:31PM Street Insider
Reviewing our covered $CALL trades on $COP & $LLY that expired back in January http://stks.co/2Hh0 $$
about 5 days ago by GlennBusch
about 5 days ago by GlennBusch
European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH
Feb 07, 8:24AM Street Insider
Feb 07, 8:24AM Street Insider
$LLY freezing pay for employees due to financial problems caused by expiration of patents http://stks.co/2F9B
about 8 days ago by sld
about 8 days ago by sld
$LLY trading above 10DMA on high advancing volume today & yesterday.
about 12 days ago by stubbybrown
about 12 days ago by stubbybrown
bill gunderson's daily stock market radio show will be live in 15 min. $PFE $NHI $LLY etc. #Howard Lindzon on next week.
about 12 days ago by billgunderson
about 12 days ago by billgunderson
RT @lamonicabuzz Pfizer, Eli Lilly beat on EPS & sales. $PFE $LLY each up 1% pre-market despite $PFE outlook cut on strong $.
about 12 days ago by StockTwits
about 12 days ago by StockTwits
This is your market on drugs. Pfizer, Eli Lilly beat on EPS & sales. $PFE $LLY each up 1% pre-market despite $PFE outlook cut on strong $.
about 12 days ago by lamonicabuzz
about 12 days ago by lamonicabuzz
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LLY | 39.31 | -0.21 | -0.53% | 45.51B |
| JPM | 37.61 | -0.25 | -0.66% | 142.91B |
| ICGE | 9.85 | -0.15 | -1.50% | 364.15M |
| RNOW | 43.00 | 0.19 | 0.44% | 1.43B |
| GRA | 54.83 | -0.27 | -0.49% | 4.05B |
| GMCR | 62.85 | -1.40 | -2.18% | 9.72B |
| SNE | 19.53 | -0.38 | -1.91% | 19.60B |
| CUBA | 7.00 | -0.02 | -0.30% | |
| COF | 48.28 | -0.82 | -1.67% | 22.19B |
| RUE | 26.23 | 0.15 | 0.58% | 641.59M |
